Literature DB >> 2996907

Blood pressure response to enalaprilic acid in essential hypertension: dose-response and effect of pre-treatment with furosemide.

G J Navis, P E de Jong, A J Donker, G K van der Hem, D de Zeeuw.   

Abstract

Enalaprilic acid (MK 422), the active metabolite of enalapril, has recently become available for intravenous administration. In order to establish the proper dose for rapid blood pressure reduction, 9 patients with moderate to severe essential hypertension on a constant sodium intake of 100 mmol/24h were studied. They received four single doses of MK 422 according to an up-and-down titration schedule. Doses between 5 and 80 mg resulted in effective blood pressure reduction with an onset of action of about 10 minutes. Within this dose range the response was flat. No symptomatic hypotension was observed. The fall in blood pressure was less pronounced in patients with low initial plasma renin activity (PRA). Accordingly, a study was done to show whether the blood pressure response could be augmented by preceding stimulation of PRA by injection of 40 mg furosemide 15 minutes before the administration of MK 422. PRA increased after furosemide, but the blood pressure response to MK 422 was not augmented.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996907     DOI: 10.1007/bf00547361

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  The early effects of intravenous frusemide on central haemodynamics, venous tone and plasma renin activity.

Authors:  B Hesse; I Nielsen; H Lund-Jacobsen
Journal:  Clin Sci Mol Med       Date:  1975-12

2.  Mechanism of the effects of furosemide on renin secretion in anesthetized dogs.

Authors:  A J Vander; J Carlson
Journal:  Circ Res       Date:  1969-08       Impact factor: 17.367

3.  Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Authors:  H Gavras; J Biollaz; B Waeber; H R Brunner; I Gavras; R O Davies
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

4.  Special problems in the radioimmunoassay of plasma aldosterone without prior extraction and purification.

Authors:  J J Pratt; R Boonman; M G Woldring; A J Donker
Journal:  Clin Chim Acta       Date:  1978-03-15       Impact factor: 3.786

5.  Response of the kidney to furosemide. II. Effect of captopril on sodium balance.

Authors:  R A Kelly; C S Wilcox; W E Mitch; T W Meyer; P F Souney; C M Rayment; P A Friedman; S L Swartz
Journal:  Kidney Int       Date:  1983-08       Impact factor: 10.612

6.  Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).

Authors:  F M Fouad; R C Tarazi; E L Bravo; S C Textor
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

7.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

8.  Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

9.  Effects of enalapril, a new converting enzyme inhibitor, in hypertension.

Authors:  R K Ferguson; P H Vlasses; B N Swanson; P Mojaverian; M Hichens; J D Irvin; P B Huber
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

10.  Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination.

Authors:  P H Vlasses; H H Rotmensch; B N Swanson; J D Irvin; R B Lee; J R Koplin; R K Ferguson
Journal:  J Clin Pharmacol       Date:  1983 May-Jun       Impact factor: 3.126

  10 in total
  1 in total

1.  Enalaprilat controls postoperative hypertension while maintaining cardiac function and systemic oxygenation after neurosurgery.

Authors:  H Tohmo; M Karanko
Journal:  Intensive Care Med       Date:  1995-08       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.